Melina E. Higgins
Known title: DirectorCIK: 0001162304
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Viatris Wins FDA Approval for RYZUMVI and Advances Pacira Deal. Viatris secured U.S. FDA approval for RYZUMVI, a treatment for presbyopia, which is relevant to its partnership with Opus Genetics. The company is also moving forward with a deal involving Pacira, a development analysts are watching closely. These moves add to the company's pipeline and strategic direction.
Transaction History
| GNW | ▲ Buy | Grant | 31,547 | $285K | 5/20/2026 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 23,660 | $0 | 3/6/2026 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 1,175 | $0 | 3/6/2026 | View on chart |
| GNW | ▲ Buy | Grant | 40,904 | $285K | 5/22/2025 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 18,204 | $0 | 3/4/2025 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 773 | $0 | 3/4/2025 | View on chart |
| GNW | ▲ Buy | Grant | 41,935 | $270K | 5/23/2024 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 17,970 | $0 | 3/3/2024 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 885 | $0 | 3/3/2024 | View on chart |
| GNW | ▲ Buy | Grant | 49,342 | $270K | 5/18/2023 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 19,608 | $0 | 3/4/2023 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 705 | $0 | 3/4/2023 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 166 | $0 | 3/21/2022 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 13,996 | $0 | 3/2/2022 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 335 | $0 | 3/2/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
KBW Downgrades Genworth to Market Perform, Cuts Price Target
Keefe, Bruyette & Woods downgraded Genworth Financial to Market Perform from Outperform, lowering its price target to $10.50. The firm cited Voya Financial as a key reason for the reduced outlook. The stock is currently trading near its 52-week high, with an average analyst target of $11.50.
KBW Downgrades Genworth to Market Perform, Cuts Price Target. Keefe, Bruyette & Woods downgraded Genworth Financial to Market Perform from Outperform, lowering its price target to $10.50. The firm cited Voya Financial as a key reason for the reduced outlook. The stock is currently trading near its 52-week high, with an average analyst target of $11.50.